Similar results were reported in a network meta-analysis including 25,966 patients with T2DM, which compared GLP-1 RAs to placebo or no treatment (HR = 0.94, 95%CI = 0.76–1.16) (Zheng et al., 2018). This evidence concerns the gene GCG and type 2 diabetes mellitus.